Stock Groups

EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: A building in Tarrytown is decorated with the Regeneron Pharmaceuticals brand logo. It can be viewed on September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid

(Reuters] – An EU drug regulator stated that it is examining a marketing authorization for an antibody combination developed by Roche and Regeneron (NASDAQ) to treat and prevent COVID-19 among people over 12.

European Medicines Agency (EMA) said Monday that they will evaluate the benefits and risks of Ronapreve and could give an opinion within two weeks. It has begun a continuous review of the treatment.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]